
It's a double date, ESPP style!
This special double session will explore the various challenges when designing and operating an employee stock purchase plan (with data analytics to boot), with the first session focusing on general and U.S. specific issues and the second session focusing on non-U.S. issues.
SESSION I: ESPP - General and U.S. Issues:
The first session will focus on general and U.S. challenges to offering a Section 423-compliant employee stock purchase plan, including design issues such as setting maximum share limits, defining eligible compensation, deciding whether to allow increases during offering periods, as well as operational issues such as managing the $25,000 limit, dealing with leaves of absence and reporting disqualifying (and qualifying") dispositions.
SESSION II: ESPP - Non-U.S. Issues
The second session will focus on non-U.S. challenges to offering an employee stock purchase plan (that is intended to be Section 423-compliant within the U.S.) outside the U.S., including design issues such as using a non-423 sub-plan versus separate offerings to allow for different treatment required under local laws as well as operational issues such as managing payroll deductions and conversions on a global basis, withholding taxes at purchase, dealing with mobile employees and deciding whether and how to offer the plan in particularly challenging jurisdictions such as the EU, China, Vietnam.
NOTE: Due to a technical error, some slides did not display during the webinar.
Presenters:
Barbara Klementz
Partner, Baker McKenzie
Sinead Kelly
Partner, Baker McKenzie
Robyn Shutak
Equity Advisory Services Practice Leader, Computershare
Download the presentation
Our latest insights
View all insights

Why bank loans require more than a securities playbook

How to win back time in your middle office and refocus on strategic work

How much are unclear communications costing your financial institution?
A New Form of Share Ownership: Issuer-Sponsored Tokens

Delivering expertise in complex M&A and CVR transactions for a global pharmaceutical company

Georgeson Advisory ranked #1 by Bloomberg Activism League Tables in Europe and APAC and #3 globally

9 ways to stay ahead of regulatory deadlines without burnout

Top 9 entity compliance risks (and how to avoid them)

An early look at the 2026 proxy season

7 ways general counsels can reduce legal risk through better entity oversight

